Company Intelligence
WuXi AppTec
无锡药明康德
Under Congressional Pressure
WuXi AppTec is NOT on the Section 1260H list and has NOT been formally designated as a Biotechnology Company of Concern (BCC). However, WuXi was central to the BIOSECURE Act legislative debate and faces sustained congressional pressure. BCC status depends on the OMB Category B interagency review process. Both WuXi AppTec and WuXi Biologics have undertaken corporate restructuring intended to address concerns.
Overview
WuXi AppTec (药明康德) is the world's largest pharmaceutical contract research and manufacturing organization (CDMO/CRO) by revenue. The company provides drug discovery, development, and manufacturing services to over 6,000 clients globally, including the majority of the top 20 global pharmaceutical companies. WuXi is at the center of the BIOSECURE Act debate.
Key Facts
- 79% of US biotechs have at least one WuXi contract — the most concentrated CDMO dependency in the industry
- Revenue exceeded $5.5B in 2025, with ~30% from US clients
- Central to the BIOSECURE Act legislative debate since 2024
- Undertaking corporate restructuring and data-security measures to address congressional concerns
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Multiple (CDMO) | Ongoing | $5.5B+ annual revenue | Contract manufacturing services |
Corporate Structure
Complex group structure: WuXi AppTec (parent), WuXi Biologics (HK: 2269, partially spun off), WuXi XDC (ADC-focused, IPO planned). Multiple intermediate holding companies between operating entities and ultimate beneficial owners. This structure complicates OMB BCC subsidiary analysis under Category C.